

BIOCON GROUP

FACT SHEET

December 2011

9M FY 2012 vs. 9M FY 2011

Q3 FY 2012 vs. Q3 FY 2011

(Rs. Crores)

BIOCON LIMITED (CONSOLIDATED) UNAUDITED		
BALANCE SHEET		<i>(Rs. Crores)</i>
	December-11	March -11*
<u>SOURCES OF FUNDS</u>		
Share Capital	100	100
Reserves & Surplus	2,197	1,933
Total Shareholder's Funds	2,297	2,033
Deferred Tax Liability	42	50
Minority Interest	-	38
Secured Loans	184	204
Unsecured Loans	192	130
Total Loans	376	334
TOTAL	2,715	2,455
<u>APPLICATION OF FUNDS</u>		
Fixed Assets (Net)	1,565	1,356
Intangible Assets	250	234
Investments - Liquid Funds	575	400
Investments - Others	64	61
Inventories	383	414
Sundry debtors	480	513
Cash and bank balances	388	441
Loans and advances	225	136
Total Current Assets	1,476	1,503
Less: Current liabilities	1,215	1,100
Net Current assets	261	403
TOTAL	2,715	2,455
* including Axicorp		

**BIOCON LIMITED (CONSOLIDATED) UNAUDITED
PROFIT & LOSS STATEMENT** (Rs. Crores)

Particulars	Q3 FY 12	Q2 FY 12	Variance	Q3 FY 11	Variance
INCOME					
Biopharmaceuticals	335	351	-5%	384	-13%
Branded formulations - India	70	65	8%	47	49%
Total Biopharmaceuticals	405	416	-3%	431	-6%
Contract research	112	93	21%	79	42%
Total Sales	517	509	2%	510	1%
Other income	15	16	-6%	9	74%
Total Revenue	532	525	1%	519	3%
EXPENDITURE					
Material & Power Costs	233	237	-2%	206	13%
Staff costs	73	72	1%	57	29%
Research & Development	33	31	8%	55	-40%
Other Expenses	51	34	45%	30	72%
Manufacturing, staff & other expenses	390	374	4%	348	12%
PBDIT /EBITDA	142	150	-5%	171	-17%
Interest and finance charges	3	2	45%	6	-54%
Depreciation & Amortisation	43	43	1%	39	11%
PBT	96	105	-8%	126	-23%
Taxes	11	19	-40%	27	-58%
NET PROFIT (PAT) WITHOUT AXICORP	85	86	-1%	99	-14%
Profit from discontinued (AxiCorp) Operations, net	-	-	-	2	
NET PROFIT FOR THE PERIOD	85	86	-1%	101	-16%
EPS Rs.	4.2	4.3		5.0	
<i>Note: The figures are rounded off to nearest crores, percentages are based on absolute numbers</i>					
Biopharmaceuticals Income includes:					
Licensing development fees	29	36		58	
Licensing Income	-	1		19	

BIOCON LIMITED (CONSOLIDATED) UNAUDITED			
PROFIT & LOSS STATEMENT			
<i>(Rs. Crores)</i>			
Particulars	9M FY 12	9M FY 11	Variance
<u>INCOME</u>			
Biopharmaceuticals	983	966	2%
Branded formulations - India	192	136	40%
Total Biopharmaceuticals	1,175	1,102	7%
Contract research	292	229	28%
Total Sales	1,467	1,331	10%
Other income	44	24	79%
Total Revenue	1,511	1,355	11%
<u>EXPENDITURE</u>			
Material & Power Costs	682	590	16%
Staff costs	210	160	31%
Research & Development	84	96	-13%
Other Expenses	110	83	32%
Manufacturing, staff & other expenses	1,086	929	17%
PBDIT /EBITDA	425	426	0%
Interest and finance charges	11	19	-45%
Depreciation & Amortisation	131	113	16%
PBT	283	294	-4%
Taxes	42	48	-13%
NET PROFIT (PAT) WITHOUT AXICORP	241	246	-2%
Profit from discontinued (AxiCorp) Operations, net	-	21	
NET PROFIT FOR THE PERIOD	241	267	-10%
EPS Rs.	12.0	13.4	
<i>Note: The figures are rounded off to nearest crores, percentages are based on absolute numbers</i>			
<i>Biopharmaceuticals Income includes:</i>			
<i>Licensing development fees</i>	79	58	
<i>Licensing Income</i>	1	62	